Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04885-5 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Islam Nouh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Benha University, Benha, Qalubia, Egypt. Hauptthemen laut MEDLINE: Indoles, Contraceptive Agents, Male. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To assess the efficacy of silodosin 8 mg as potentially reversible male contraceptive. METHODS: In all, 200 healthy, sexually active, fertile male candidates were assigned as follows: 100 in silodosin group and 100 in placebo group. Males using other contraceptive methods were excluded. Follow up data of total spermatozoa per ejaculate, semen volume and post-ejaculation urinalysis after 2, 6 and 12 weeks of the studied groups were recorded. The various side effects reported in the study groups after 12 weeks from the start of the study were recorded. MAIN OUTCOME MEASURES: The primary outcome measure was the treatment period and pregnancy rate during the study to evaluate silodosin contraceptive efficacy. The secondary outcome measure was intolerance to the drug due to adverse events leading to dropping out of the study. RESULTS: After 3 months, total spermatozoa per ejaculate and semen volume in silodosin group were 0.113 ± 0.480 (0.0003-3.1) and 0.600 ± 0.028 (0.55-0.64) respectively that were highly significantly decreased compared to placebo group 75.967 ± 5.105 (66.4-85.90) and 2.415 ± 0.278 (1.99-3.03) respectively, p < 0.001. Side effects in the study groups after 3 months, silodosin group significantly suffered from stuffy nose, dizziness, weakness and scanty ejaculate (26%, 17%, 15% and 84%, respectively) higher than placebo group (4%, 2%, 4% and 6%, respectively), with highly significant difference between groups, p < 0.001, < 0.001, 0.008 and < 0.001, respectively). Silodosin group significantly had lower pregnancy incidence (4%) compared to placebo group (17%), p < 0.001. CONCLUSION: Silodosin 8 mg yields a better sperm suppression results as on-demand male contraception after 3 months of continuous daily oral intake when compared to placebo, associated with pregnancy rate of 4% and higher but tolerable side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology Department, Benha University, Benha, Qalubia, Egypt.
- Urology Department, University Hospitals Coventry and Warwickshire, Coventry, UK.
- Urology Department, Benha University, Benha, Qalubia, Egypt. drfarag66@gmail.com.
Zitieren
APA
Nouh, I., Eldib, H., Noah, K., & Farag, M. (2025). Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04885-5
Vancouver
Nouh I, Eldib H, Noah K, Farag M. Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04885-5
BibTeX
@article{Nouh2025,
author = {Nouh, Islam and Eldib, Helmy and Noah, Kareem and Farag, Mahmoud},
title = {Efficacy of daily silodosin 8 mg as a potential reversible male contraceptive: A prospective placebo controlled study},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04885-5}
}
EUVIMED